Lisata Therapeutics, based in Basking Ridge, New Jersey, focuses on developing therapies for advanced solid tumors, with its lead candidate LSTA1 enhancing anti-cancer drug penetration in tumors. The company also explores CD34+ cell therapy for various diseases, including critical limb ischemia and diabetic kidney disease.
LSTA has been in the news recently: LISATA THERAPEUTICS is not mentioned in the provided information. The details focus on various biotech companies, including IDEAYA Biosciences receiving FDA Breakthrough Therapy designation for darovasertib and Neurocrine Biosciences' INGREZZA® achieving a therapeutic dose for all patients from day one.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
